Cryocompression May Mitigate Chemo-Induced Neuropathy in Gynecologic Cancers


Investigators report that most patients with gynecologic cancers were able to tolerate cryocompression to help manage chemotherapy-induced neuropathy, according to an expert from Duke University Medical Center.

Cryocompression may help to prevent peripheral neuropathy related to chemotherapy for patients diagnosed with gynecologic cancers without additional burden, according to Mary Katherine Montes de Oca, MD.

During The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Montes de Oca, an Obstetrics and Gynecology resident at Duke University Medical Center, about data from a study evaluating the efficacy and patient-reported outcomes of cryocompression in preventing peripheral neuropathy following chemotherapy for gynecologic cancers as well as patient-reported.

In the self-controlled trial, over 70% of patients reported cryocompression was very tolerable with each cycle, and over 80% “agreed” or “strongly agreed” that cryocompression was acceptable and planned to continue with the intervention during future chemotherapy. Additionally, patients undergoing cryocompression were 39% less likely to report Patient Neurotoxicity Questionnaire grade of C or less symptoms of peripheral neuropathy compared with a control group of patients who did not undergo cryocompression.


We found that cryocompression therapy significantly prevented subjective symptoms of neuropathy. We didn’t find any differences in objective neuropathy between groups, and we found that patients overall were able to tolerate the cryocompression really well.

There’s a theoretical concern of frostbite from the ice on the hands and feet. We didn’t have any adverse [effects] from use of the cryocompression. There were 2 patients who weren’t able to tolerate the treatment. But the compression therapy can also allow for a barrier between the patient’s fingertips and the ice.

I hope that [my colleagues] take away that cryocompression can prevent chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Hopefully, it is something that is easy, accessible, and [is something] that can be recommend to patients without creating additional burden on them during chemotherapy.


Montes de Oca MK, Unnithan S, Erkanli AE, et al. Use of cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Related Videos
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Sean Dineen, MD, highlights the removal of abdominal wall lesions and other surgical strategies that may help manage symptoms in patients with cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Related Content